Oatly Group AB ADROTLY
Mentioned
Impact on stocks 1
Synthetic Biology (non-pharma)
Oatly Group AB ADROatly Group AB ADROatly Group AB reported stronger-than-expected second-quarter 2026 results, with revenue of $240.1 million beating analysts' consensus estimate of $220.1 million and prompting the company to raise its full-year sales outlook. The oat-based beverage maker posted a 15% increase in revenue from a year earlier and an adjusted loss of $0.99 per ADS, outperforming market expectations for a loss of $1.02. Following the results, Oatly increased its full-year constant currency revenue growth guidance to between 8% and 10%, up from its previous forecast of 3% to 5%, while leaving its adjusted EBITDA guidance unchanged at $25 million to $35 million. Revenue increased across all operating markets, with Europe & International leading at $143.1 million, up 21% year over year, North America at $66.9 million, up 5.9%, and Greater China at $30.1 million, up 11.6%. Adjusted EBITDA turned positive at $0.4 million compared with a loss of $3.6 million in the prior-year quarter, and the net loss narrowed to $31.3 million from $55.9 million a year earlier. Oatly shares surged more than 16% in premarket trading.
Oatly Group AB ADR